EGFR, epidermal growth factor receptor, 1956

N. diseases: 1394; N. variants: 183
Disease: Lung adenocarcinoma recurrent ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0854983
Disease: Lung adenocarcinoma recurrent
Lung adenocarcinoma recurrent 		0.050 Biomarker disease BEFREE The patients in Cohort 1 received epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for recurrent lung adenocarcinoma. 31462002 2019
CUI: C0854983
Disease: Lung adenocarcinoma recurrent
Lung adenocarcinoma recurrent 		0.050 GeneticVariation disease BEFREE Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery. 30290774 2018
CUI: C0854983
Disease: Lung adenocarcinoma recurrent
Lung adenocarcinoma recurrent 		0.050 GeneticVariation disease BEFREE We retrospectively analyzed 142 patients with EGFR-mutation positive advanced or recurrent lung adenocarcinoma who were administered gefitinib, erlotinib, afatinib, and osimertinib. 30055587 2018
CUI: C0854983
Disease: Lung adenocarcinoma recurrent
Lung adenocarcinoma recurrent 		0.050 Biomarker disease BEFREE New EGFR-TKI: a case report of recurrent lung adenocarcinoma successfully treated with icotinib. 23052173 2012
CUI: C0854983
Disease: Lung adenocarcinoma recurrent
Lung adenocarcinoma recurrent 		0.050 GeneticVariation disease BEFREE Although specific clinical circumstances should guide therapy, our cost-effectiveness analysis supports the strategy of testing for EGFR mutations in patients with stage IV or recurrent adenocarcinoma of the lung, rebiopsying patients if insufficient tissue is available for testing, and treating patients with EGFR mutations with erlotinib as first-line therapy. 23277762 2012